CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 48 enrolled
Drug / intervention
Fondaparinuxdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00320424
NCT00320424Phase 3Completed
CompareCT.gov

Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Hip Fracture Surgery

GlaxoSmithKline·interventional·Posted May 3, 2006·Updated Sep 4, 2018

In Brief

A Phase 3 clinical trial evaluating Fondaparinux for Thromboembolism. Completed, enrolled 48 participants across 1 site.

Detailed Summary

This study is requested by PMDA to confirm the efficacy and the safety for HFS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThromboembolism
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 3, 2006
Enrollment StartFeb 16, 2006
Primary CompletionOct 26, 2006
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 20.2 years ago

Interventions

Fondaparinuxdrug